Drug-eluting stents in the treatment of atherosclerotic coronary heart disease

Indian Heart Journal

Volumn 54, Issue 2, 2002, Pages 212-216

  Lemos, Pedro A ^a   Regar, Evelyn ^a   Serruys, Patrick W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DACTINOMYCIN; PACLITAXEL; RAPAMYCIN;

ATHEROSCLEROSIS; CLINICAL TRIAL; DEVICE; DRUG COATING; ELUTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; ISCHEMIC HEART DISEASE; META ANALYSIS; PATHOPHYSIOLOGY; RESTENOSIS; REVIEW; STENT; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CORONARY ARTERIOSCLEROSIS; CORONARY RESTENOSIS; DACTINOMYCIN; DRUG IMPLANTS; HUMANS; PACLITAXEL; SIROLIMUS; STENTS; TREATMENT OUTCOME;

EID: 0036081325     PISSN: 00194832     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. ACC/AHA guidelines of percutaneous coronary interventions (revision of the 1993 PTCA guidelines - Executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty)
2. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease
3. A comparison of coronary-artery stenting with angioplasty for isolated stenosis of the proximal left anterior descending coronary artery
4. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease
5. Clinical and quantitative coronary angiographic predictors of coronary restenosis: A comparative analysis from the balloon-to-stent era
6. Periprocedural quantitative coronary angiography after Palmaz-Schatz stent implantation predicts the restenosis rate at six months: Results of a meta-analysis of the BElgian NEtherlands Stent study (BENESTENT) I. BENESTENT II Pilot, BENESTENT II and MUSIC trials. Multicenter Ultrasound Stent In Coronaries
7. Angiographic patterns of in-stent restenosis: Classification and implications for long-term outcome
8. New frontiers in interventional cardiology: Intravascular radiation to prevent restenosis
9. Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study
10. Pathology of in-stent restenosis
11. Gene expression profiling of human stent-induced neointima by cDNA array analysis of microscopic specimens retrieved by helix cutter atherectomy: Detection of FK506-binding protein 12 upregulation
12. Anti-restenosis trials
13. Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: A serial intravascular ultrasound study
14. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis
15. Coronary stent coatings
16. Synthetic polymers
17. Coated and active stents: An introduction
18. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries
19. Microtubules
20. Paclitaxel (taxol)
21. Taxol stabilizes microtubules in mouse fibroblast cells
22. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations
23. Novel drug-delivery stent: Intravascular ultrasound observations from the first human experience with the QP2-eluting polymer stent system
24. Inhibition of smooth muscle cell proliferation after local drug delivery of the antimitotic drug paclitaxel using a porous balloon catheter
25. Paclitaxel-coated Gianturco-Roubin II (GR II) stents reduce neointimal hyperplasia in a porcine coronary in-stent restenosis model
26. Highlights from the American Heart Association annual scientific sessions 2001: November 11 to 14, 2001
27. Initial results of the Quanam drug eluting stent (QuaDS-QP-2) Registry (BARDDS) in human subjects
28. Late acute thrombosis after paclitaxel eluting stent implantation
29. Role for p27(Kip1) in vascular smooth muscle cell migration
30. Bench to bedside: The development of rapamycin and its application to stent restenosis
31. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle
32. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model
33. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: One-year angiographic and intravascular ultrasound follow-up
34. Lack of edge effect in sirolimus coated Bx velocity stent
35. Coronary restenosis elimination with a sirolimus eluting stent: First European human experience with 6-month angiographic and intravascular ultrasonic follow-up
36. The RAVEL study: A randomized study with the sirolimus coated Bx velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions
37. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent
38. Living the dream of no restenosis
39. Physiological transport forces govern drug distribution for stent-based delivery
40. Inhibition of neointima formation after experimental coronary artery stenting: A new biodegradable stent coating releasing hirudin and the prostacyclin analogue iloprost
41. Intravascular local gene transfer mediated by protein-coated metallic stent
42. Intramural delivery of a specific tyrosine kinase inhibitor with biodegradable stent suppresses the restenotic changes of the coronary artery in pigs in vivo
43. Effect of local delivery of L-arginine on in-stent restenosis in humans
44. Evaluation of local abciximab delivery from the surface of a polymer-coated covered stent: In vivo canine studies
45. Local angiopeptin delivery using coated stents reduces neointimal proliferation in overstretched porcine coronary arteries